Canadian biopharmaceutical company Find Therapeutics has dosed the first subject in a Phase I trial of its lead compound, FTX-101, as a potential treatment for chronic optic neuropathy.
The company received approval for the two-part trial from the US Food and Drug Administration earlier this year.
Go deeper with GlobalData
Part I is a double-blind, randomised, placebo-controlled, single-ascending dose (SAD) study enrolling 40 subjects, while the second part is a multiple-ascending dose (MAD) study that will enrol 24 subjects.
The study aims to evaluate the safety, tolerability and pharmacokinetics of FTX-101 versus placebo in healthy volunteers.
Find Therapeutics expects to release data from the trial in the first half of next year.
FTX-101 is designed as a remyelinating agent that could restore vision for individuals suffering from chronic optic neuropathy, a condition resulting from demyelination in the visual pathways.
How well do you really know your competitors?
Access the most comprehensive Company Profiles on the market, powered by GlobalData. Save hours of research. Gain competitive edge.
Thank you!
Your download email will arrive shortly
Not ready to buy yet? Download a free sample
We are confident about the unique quality of our Company Profiles. However, we want you to make the most beneficial decision for your business, so we offer a free sample that you can download by submitting the below form
By GlobalDataThe therapeutic peptide modulates the Plexin A1 / Neuropilin 1 receptor complex in the brain to promote remyelination.
Preclinical data have shown that FTX-101 demonstrates strong myelin repair activity.
Find Therapeutics CEO Philippe Douville said: “The initiation of this study is a significant milestone for both our company and individuals who suffer from chronic optic neuropathy.
“In this study, we will build on the large body of preclinical evidence demonstrating FTX-101’s effects in models of autoimmune disease.
“A therapy of this type would represent a major step forward in finding the first treatment to improve the lives of people afflicted with chronic optic neuropathy.”
Founded in 2020, Find Therapeutics aims to develop next-generation therapies for inflammatory autoimmune diseases.
The company has been supported by CTI Life Sciences, adMare BioInnovations, Domain Therapeutics and Investissment Québec, as well as SATT-Conectus and the University of Strasbourg.
Last month, it raised C$11m ($8.1m) in a convertible note financing round held to advance FTX-101 into Phase I clinical studies.
